关注并星标CPHI制药在线近日,各家药企开始披露今年第三季度业绩报告,其中艾力斯和君实生物均是依靠核心大单品,赢得业绩持续稳步增长。艾力斯多年来持续深耕肺癌领域,君实生物在PD-1单抗领域取得成绩后,再聚焦双抗、ADC领域,逐步完成蜕变。两家创新药企在中国Biotech里,是少数靠销售业绩打拼出一片天的公司,它们在用各自的方式,展现“聚焦”的力量。艾力斯:以价换量,后来居上今年前三季度,艾力斯营业...
Source Link关注并星标CPHI制药在线近日,各家药企开始披露今年第三季度业绩报告,其中艾力斯和君实生物均是依靠核心大单品,赢得业绩持续稳步增长。艾力斯多年来持续深耕肺癌领域,君实生物在PD-1单抗领域取得成绩后,再聚焦双抗、ADC领域,逐步完成蜕变。两家创新药企在中国Biotech里,是少数靠销售业绩打拼出一片天的公司,它们在用各自的方式,展现“聚焦”的力量。艾力斯:以价换量,后来居上今年前三季度,艾力斯营业...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.